var data={"title":"Ferric carboxymaltose: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ferric carboxymaltose: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/684730?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ferric-carboxymaltose-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ferric carboxymaltose: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21196340\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Injectafer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099107\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iron Salt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283745\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose expressed as elemental iron</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron-deficiency anemia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;50 kg: 15 mg/kg elemental iron on day 1; repeat dose after at least 7 days (maximum: 1,500 mg elemental iron per course). May repeat course of therapy if anemia reoccurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;50 kg: 750 mg on day 1; repeat dose after at least 7 days (maximum: 1,500 mg per course). May repeat course if anemia reoccurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (off-label use): </b>IV: 500 mg on day 1; repeat after 5 days (AAN [Winkelman 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283746\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283747\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Chronic kidney disease, nondialysis dependent: No dosage adjustment necessary (indicated for use in nondialysis CKD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283748\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21196341\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injectafer: 750 mg/15 mL (15 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21196339\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963469\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Each mL of Injectafer contains 50 mg of elemental iron</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283749\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as slow IV push (undiluted) at a rate of ~100 mg/minute or as an IV infusion (diluted) over at least 15 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avoid extravasation (may cause persistent discoloration at the extravasation site). Monitor; if extravasation occurs, discontinue administration at that site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099097\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Iron deficiency anemia:</b> Treatment of iron deficiency anemia (IDA) in adults with intolerance to oral iron or unsatisfactory response to oral iron; treatment of IDA in adults with nondialysis-dependent chronic kidney disease (ND-CKD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50946856\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Restless legs syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283278\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ferric carboxymaltose may be confused with ferric gluconate, ferumoxytol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21304014\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Decreased serum phosphate (27%; &lt;2 mg/dL [0.65 mmol/L]; transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Increased blood pressure (6%; transient, systolic), flushing (4%), hypertension (4%), hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (2%), headache (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin discoloration at injection site (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypophosphatemia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (7%), vomiting (2%), constipation (1%), dysgeusia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylaxis, angioedema, arthralgia, back pain, chest discomfort, chills, diarrhea, dyspnea, erythema, fever, hypersensitivity, increased gamma-glutamyl transferase, irritation at injection site, pain at injection site, paresthesia, pruritus, skin rash, sneezing, syncope, tachycardia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099098\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ferric carboxymaltose or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283284\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious hypersensitivity reactions, including anaphylactic-type reactions (some life-threatening and fatal) have been reported. Monitor during and for at least 30 minutes after administration and until clinically stable. Signs/symptoms of serious hypersensitivity reaction include shock, hypotension, loss of consciousness, and/or collapse. Equipment for resuscitation, medication, and trained personnel experienced in handling emergencies should be immediately available during infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Transient elevations in systolic blood pressure (sometimes with facial flushing, dizziness, or nausea) were observed in studies; usually occurred immediately after dosing and resolved within 30 minutes. Monitor blood pressure following infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory alterations: Lab assays may overestimate serum iron and transferrin bound irons for ~24 hours after infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21213087\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21213085\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=90237&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283281\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Ferric carboxymaltose has been evaluated for the treatment of iron deficiency anemia (IDA) during pregnancy (Aporta Rodriguez 2016; Breymann 2017; Froessler 2014; Pels 2015) and postpartum (Breymann 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated IDA is associated with adverse pregnancy outcomes including low birth weight, preterm delivery, and maternal postpartum anemia.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Iron requirements increase during pregnancy. All females should be screened for iron deficiency during pregnancy; if IDA is present, supplemental iron (in addition to prenatal vitamins) should be administered. Oral preparations are generally sufficient, however parenteral iron therapy may be used in females who cannot tolerate or will not take oral iron, in cases of severe iron deficiency, or when malabsorption is present (ACOG 95 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283283\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron concentrations in breast milk increase following maternal administration of ferric carboxymaltose (Breymann 2008). Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants (IOM 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Infants should be monitored for gastrointestinal toxicity, such as constipation or diarrhea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283804\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin and hematocrit, serum ferritin, iron saturation; vital signs (including blood pressure); signs and symptoms of hypersensitivity (monitor for &ge;30 minutes following the end of administration and until clinically stable); monitor infusion site for extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NKF KDOQI guidelines (2006) recommend monitoring iron status every 1-3 months, with more frequent monitoring after course of IV iron therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283472\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">CKD patients should have sufficient iron to achieve and maintain hemoglobin of 11 to 12 g/dL; to achieve and maintain this target hemoglobin for patients with nondialysis dependent CKD, sufficient iron should be administered to maintain a transferrin saturation (TSAT) of 20%, and a serum ferritin level &ge;100 ng/mL (NKF KDOQI 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283470\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron necessary to the function of hemoglobin, myoglobin, and specific enzyme systems; allows transport of oxygen via hemoglobin. Ferric carboxymaltose is a non-dextran formulation that allows for iron uptake (into reticuloendothelial system) without the release of free iron (Szczech 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21287590\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~3 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 7 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 0.25 to 1.2 hours following administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (negligible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22686900\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Injectafer Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg/15 mL (15 mL): $1,204.78</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23669728\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ferinject (AR, AT, AU, BR, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HR, HU, IE, IL, IS, KR, LB, LT, LV, MT, NL, NO, NZ, PE, PL, PT, RO, SA, SE, SG, SK);</li>\n      <li>Ferium (CL);</li>\n      <li>Ferynzhekt (UA);</li>\n      <li>Injectafer (BE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: anemia in pregnancy. <i>Obstet Gynecol</i>. 2008;112(1):201-207. doi: 10.1097/AOG.0b013e3181809c0d.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/18591330/pubmed\" target=\"_blank\" id=\"18591330\">18591330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anker SD, Comin Colet J, Filippatos G, et al, &ldquo;Ferric carboxymaltose in patients with heart failure and iron deficiency,&rdquo; <i>N Engl J Med</i>, 2009, 361(25):2436-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/19920054/pubmed\" target=\"_blank\" id=\"19920054\">19920054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aporta Rodriguez R, Garc&iacute;a Montero M, Lorente Aporta JP, et al. Retrospective case reports of anemic pregnant women receiving intravenous ferric carboxymaltose: experience from a tertiary hospital in Spain. <i>Obstet Gynecol Int</i>. 2016;2016:5060252. doi: 10.1155/2016/5060252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27840641/pubmed\" target=\"_blank\" id=\"27840641\">27840641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18234203\"></a>Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. <i>Int J Gynaecol Obstet</i>. 2008;101(1):67-73. doi: 10.1016/j.ijgo.2007.10.009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J; FER-ASAP investigators. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). <i>J Perinat Med</i>. 2017;45(4):443-453. doi: 10.1515/jpm-2016-0050.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27278921/pubmed\" target=\"_blank\" id=\"27278921\">27278921</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. <i>BMC Pregnancy Childbirth</i>. 2014;14:115. doi: 10.1186/1471-2393-14-115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/24667031/pubmed\" target=\"_blank\" id=\"24667031\">24667031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Injectafer (ferric carboxymaltose) [prescribing information]. Shirley, NY: American Regent Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine). <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>. Washington, DC: National Academy Press; 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo; Am J Kidney Dis, 2007, 50(3):529-30. Available at http://www2.kidney.org/professionals/KDOQI/guidelines_anemiaUP/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo; Am J Kidney Dis, 2006, 47(5):S1-S145. Available at https://www.kidney.org/sites/default/files/docs/anemiainckd.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pels A, Ganzevoort W. Safety and efficacy of ferric carboxymaltose in anemic pregnant women: a retrospective case control study. <i>Obstet Gynecol Int</i>. 2015;2015:728952. doi: 10.1155/2015/728952.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/26688686/pubmed\" target=\"_blank\" id=\"26688686\">26688686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qunibi WY, Martinez C, Smith M, et al, &ldquo;A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients,&rdquo; <i>Nephrol Dial Transplant</i>. 2011, 26(5):1599-607.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/20929915/pubmed\" target=\"_blank\" id=\"20929915\">20929915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szczech LA, Bregman DB, Harrington RA, et al &ldquo;Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design,&rdquo; <i>Nephrol Dial Transplant</i>, 2010, 25(7):2368-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/20466657/pubmed\" target=\"_blank\" id=\"20466657\">20466657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2016;87(24):2585-2593. doi: 10.1212/WNL.0000000000003388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27856776/pubmed\" target=\"_blank\" id=\"27856776\">27856776</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 90237 Version 79.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F21196340\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F21099107\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F21283745\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F21283746\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F21283747\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F21283748\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F21196341\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F21196339\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963469\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F21283749\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F21099097\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50946856\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F21283278\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F21304014\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F21099098\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F21283284\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F21213087\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F21213085\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F21283281\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21283283\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F21283804\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F21283472\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F21283470\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F21287590\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F22686900\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23669728\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/90237|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ferric-carboxymaltose-patient-drug-information\" class=\"drug drug_patient\">Ferric carboxymaltose: Patient drug information</a></li></ul></div></div>","javascript":null}